Search
Cenisertib
go.drugbank.com/drugs/DB06347InvestigationalCenisertib is an aurora kinase inhibitor.
Categories: Heterocyclic Compounds, 1-RingZiconotide
go.drugbank.com/drugs/DB06283ApprovedInvestigationalsynthesized without loss of proper bond formation or structural elements. … [A202835, L13389] Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy in binding specific subsets of calcium channels; ziconotide is used in part because it can be
Categories: Compounds used in a research, industrial, or household setting, Calcium Channels, N-TypeIsotretinoin
go.drugbank.com/drugs/DB00982ApprovedInvestigationalIsotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne. … [L6574] Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in the United States.
Synonyms: Neovitamin A acid, 13-cis-Vitamin A acidMixtures: ISOTREXIN JEL, 30 G, ETREXİN % 2 + % 0.05 JELMagnesium citrate
go.drugbank.com/drugs/DB11110ApprovedInvestigational[L2831] It is also considered as an active ingredient in over-the-counter products.[L1113] … [T215] Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg.
Mixtures: Calcium Magnesium Plus Vitamin D Liquid, Calcium and Magnesium Citrate With Vitamin DProducts: Citrate of Magnesium, BET-R-PREP Magnesium Citrate OralMeglumine
go.drugbank.com/drugs/DB09415ApprovedInvestigationalSynonyms: N-methyl-D-glucamine, 1-deoxy-1-methylaminosorbitolMixtures: UROGRAFIN %76 IV ENJEKSIYON VE INFUZYON ICIN COZELTI, 100 ML, UROGRAFIN %76 IV ENJEKSIYON VE INFUZYON ICIN COZELTI, 50 MLCabozantinib
go.drugbank.com/drugs/DB08875ApprovedInvestigational[L15123] In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 … Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor.
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexAlanosine
go.drugbank.com/drugs/DB05540InvestigationalAn amino acid analogue and antibiotic derived from the bacterium Streptomyces alanosinicus with antimetabolite and potential antineoplastic activities.
Synonyms: L-AlanosineCategories: Compounds used in a research, industrial, or household settingPeginterferon beta-1a
go.drugbank.com/drugs/DB09122ApprovedInvestigational[L5801] MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men. … [L31428] Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS.
Synonyms: PEG IFN-beta-1aMixtures: PLEGRİDY 63 MCG/0.5 ML+94 MCG/0.5 ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM TEDAVİYE BAŞLAMA PAKETİ , 1 ADET 63 MGC/0.5 ML+1 ADET 94 MCG/0.5 ML, PLEGRİDY 63 MCG/0.5 ML+94 MCG/0.5 ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM TEDAVİYE BAŞLAMA PAKETİ , 1 ADET 63 MGC/0.5 ML+1 ADET 94 MCG/0.5 MLSilodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigationalSilodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder … [A231159] Silodosin was first approved by the FDA in October 2008 [A231159] and it is also approved in Europe and Canada.
Categories: Drugs Used in Benign Prostatic Hypertrophy, Cytochrome P-450 SubstratesProducts: SILOPROST® 8, FENANTA® 8 MGTenapanor
go.drugbank.com/drugs/DB11761ApprovedInvestigationala novel alternative in the treatment of IBS-C. … Tenapanor is a novel, small molecule medication approved in September 2019 for the treatment of constipation-predominant irritable bowel-syndrome (IBS-C).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates